Drug developers take fresh aim at 'guided-missile' cancer drugs


  • World Premium
  • Monday, 06 Jan 2020

FILE PHOTO: A scientist studies cancer cells inside white blood cells through a microscope at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls/File Photo

FRANKFURT/ZURICH (Reuters) - Dozens of drugmakers are conducting human trials for a record 89 therapies that pair antibodies with toxic agents to fight cancer, evidence of renewed confidence in an approach that has long fallen short of its promise, an analysis compiled for Reuters shows.

These antibody-drug conjugates, or ADCs, from companies including AztraZeneca and GlaxoSmithKline, are described by researchers as "guided missiles" packing a powerful anti-cancer punch.

Article type: metered
User access status: 3
Join our Telegram channel to get our Evening Alerts and breaking news highlights
   

Next In World

Climate change protest throws Sydney traffic into chaos, 11 arrested Premium
Russian forces turn sights on Lysychansk in battle for eastern Ukraine Premium
Brazil's Bolsonaro to announce former defense minister as running mate Premium
Ecuador oil output halved, indigenous leader says protests to carry on Premium
Ordering take-out was a life-saver for this woman Premium
Cannabis use has risen with legalization and COVID lockdowns -U.N. report Premium
Sudan accuses Ethiopia of executing 7 Sudanese soldiers, a civilian Premium
Peru truckers, farmers to strike over fuel and fertilizer costs Premium
Erdogan to meet with leaders of Sweden, Finland before NATO summit Premium
Feature: "East Meets West" concert featuring Chinese, Italian compositions held in Rome Premium

Others Also Read